Sequencing data for the manuscript "Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer"
This submission contains gzipped fastq files from paired-end targeted sequencing.
- 03/03/2023
- 242 samples
- DAC: EGAC00001003128
- Technology: HiSeq X Ten
DUO:0000006 version: 2021-02-23
health or medical or biomedical research
This data use permission indicates that use is allowed for health/medical/biomedical purposes; does not include the study of population origins or ancestry.
DUO:0000046 version: 2021-02-23
non-commercial use only
This data use modifier indicates that use of the data is limited to not-for-profit use.
Data Access Committee for the DNA sequencing data included in the study "Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer".
A data access agreement (DAA), based on the example DAA provided by EGA, is to be filled out by the requester and by Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer - Data Access Committee.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001006856 | Other |